In a ribbon blender of 1,000 L capacity operating at 12 rpm with ploughshare intensifiers, the microcrystalline phthalylsulphathiazole powder exhibits a Carr’s compressibility index of 29–33 when sampled directly after jet milling. This value routinely triggers procedural countermeasures because a dispersion coefficient of variation exceeding 8.0% within the first 6 minutes of dry blending is incompatible with the homogeneity criteria of the target premix specification. The standard mitigation protocol replaces the conventional limestone carrier with a pre-lubricated, hydrophobic precipitated silica grade conforming to ISO 3262-19, which reduces interparticle adhesion driven by triboelectric charging at relative humidity below 35%. Under these conditions, an active content of 100 g/kg premix—intended for subsequent dilution to a final medicated feed level of 0.5–2.0 kg phthalylsulphathiazole per tonne of complete feed for swine dysentery control—meets the blend uniformity acceptance value 15 prescribed in Ph. Eur. 2.9.40. Industry practice in Southeast Asian and Latin American toll manufacturing facilities documents that a stepwise geometric dilution: first a 1:5 trituration with light magnesium oxide, then a 1:20 expansion with spray-dried lactose, and finally a 1:50 masterbatch introduced into the main mixer via a vacuum-conveyed split-charge system, keeps the carryover loss below 2% and eliminates the segregation observed during downstream pneumatic transfer to automatic bagging stations. The terminal feed product, typically an all-mash or crumbled pelletized feed formulated without pre-conditioning steam exceeding 65°C to avoid premature hydrolysis of the phthalimido moiety, is administered as a metaphylactic ration for 3–7 days under veterinary prescription. Regulatory alignment in these territories is anchored to the monographs for phthalylsulfathiazole in USP 43–NF 38 and the residual depletion studies required by the VICH GL48 marker residue evaluation, while local feed additive inventories—such as the Philippine Bureau of Animal Industry Administrative Order No. 14 and the Thai Ministry of Agriculture and Cooperatives Notification BE 2558—establish the maximum inclusion rate at 300 g/tonne for non-lactating cattle with a 10-day withdrawal interval.
What limits the direct compression approach for phthalylsulphathiazole tablets above a 500 mg unit dose?
The low compactibility of the neat active—a consequence of its virtually non-deformable, orthorhombic crystal habit coupled with a critical orifice diameter of 14 mm measured on a 13 mm flat-faced punch at 30 kN compaction force—precludes robust direct compression when the individual dose exceeds 500 mg. Below that threshold, a powder blend incorporating 8 wt% pregelatinized starch (Ph. Eur. type 1500) and 0.5 wt% colloidal silicon dioxide achieves a tablet breaking force of ≥2.5 kp at a dwell time of 30 ms, but the ejection stress jumps from 12 MPa to 21 MPa when the active load surpasses 72% of the final tablet weight. Production-scale rotary presses with 45-station tooling document chipping frequencies exceeding 4% at speeds above 55 rpm unless the material is pre-conditioned by roller compaction at a hydraulic pressure of 70 bar and a roll gap of 2.0 mm, followed by oscillating milling through a 1.0 mm screen. The resultant granules, with a Hausner ratio tightened from 1.38 to 1.18, permit a compression speed of 75 rpm while keeping thickness variability within ±3%. For formulations supplying the adult human dose of 2.0–4.0 g daily in divided portions, wet granulation remains the default choice: a plow mixer granulator run at a chopper speed of 3,000 rpm with a 12% w/w aqueous polyvinylpyrrolidone K30 binder solution yields an endpoint power consumption of 16–18 A on a 150 L vessel after 7 minutes of liquid addition, corresponding to a loose bulk density increase from 0.38 g/mL to 0.58 g/mL. Tablet friability measured per USP <1216> remains below 0.8% after 100 rotations when the moisture content of the dried granulation is maintained at 1.5–2.2% and the lubricant (magnesium stearate) is limited to 0.75 wt% with a 3-minute mixing cycle in a diffusion mixer. The terminal product—a 4.0 g oblong tablet with a break line and a coating of hydroxypropyl methylcellulose 6 cps applied in a perforated pan at a bed temperature of 45°C—is assayed against the USP Phthalylsulfathiazole Tablets monograph, which requires not less than 93.0% and not more than 107.0% of label claim. For veterinary bolus presentations (calf, 6.0 g; foal, 12.0 g), the same granulation route is adapted to a single-punch eccentric press with a 25 mm oblong die, where the addition of 1.5 wt% croscarmellose sodium enables a disintegration time under 15 minutes in artificial rumen fluid at 39°C according to the BP Appendix XII B modified disintegration test for large-volume bolus forms.
The direct blending of phthalylsulphathiazole into a liquid feed environment or drinking water line for poultry introduces a distinct oxygen-mediated degradation pathway that is rarely referenced in compendial monographs but is well-characterized in tropical farm stability logs. When the drug is suspended in chlorinated municipal water (free chlorine residual 0.6–1.2 mg/L) at a target concentration of 1.5 g/L for metered dosing, the dissolution of 0.03% of the nominal dose into the aqueous phase is sufficient to generate a measurable sulfathiazole impurity within 4 hours at ambient temperatures above 30°C, as tracked by the area ratio in the USP <621> related compounds method. To maintain the impurity ceiling at ≤1.0% for a 24-hour on-farm consumption window, the water-soluble powder formulation is bulked with anhydrous dextrose and buffered to a microenvironmental pH of 5.2 ± 0.3 using a 2.0 wt% anhydrous citric acid / 1.2 wt% sodium citrate couple, then sealed in aluminium-LDPE laminate sachets with a moisture vapour transmission rate below 0.05 g/m²/day at 37°C/90% RH. Dosing proportioner equipment—typically a Dosatron D25RE2 venturi system calibrated to deliver a 1:100 stock solution—requires a pre-wetting step where the powder is first mixed into a 1:10 slurry with glycerine to prevent lumping in the stock tank. The terminal product, an oral solution generated continuously at the nipple drinker line, is administered to broilers at a rate of 20–25 mg/kg body weight per day for 5 days as a treatment for necrotic enteritis associated with Clostridium perfringens. Compliance is verified through the European Pharmacopoeia general chapter 2.2.32 spectrophotometric assay adapted for medicated drinking water and through the limits established in Directive 2002/32/EC on undesirable substances in animal feed, as the carryover into droppings poses cross-contamination risks for subsequent non-medicated poultry houses.
Oral paste for equine neonatal enteritis: shear-thinning rheology and gastric settling
The production of an oral paste containing 30% w/w phthalylsulphathiazole for foals—a formulation that must deliver a 15 g dose in a single 30 mL graduated syringe—requires a rheological design that is simultaneously pumpable during filling at 2,000 units per hour and resistant to expulsion from the stomach back into the oesophagus when administered by lay staff. Data from a continuous-flow capillary viscometer integrated into a servo-driven positive-displacement filler reveals that the system achieves the target yield stress of 250 ± 20 Pa and a plastic viscosity of 4.5 ± 0.4 Pa·s at 25°C through the combination of 8.0 wt% fumed silica (hydrophobic, surface area 220 m²/g, conforming to ISO 3262-20) and 1.2 wt% medium-chain triglycerides. The process sequence involves a double planetary mixer with a wall-scraper arm operating at 65 rpm planet and 27 rpm helical blade: first, the silica is pre-hydrated in glycerol for 20 minutes under –0.8 bar vacuum to avoid air entrainment; then the phthalylsulphathiazole powder, pre-sieved through a 250 μm sieve, is incorporated in three equal aliquots with a dwell time of 10 minutes between additions until the torque value stabilizes at 18–22 Nm. A processing risk emerges when the batch temperature drops below 18°C—the network structure fractures under the high-shear homogenization (2,500 rpm Silverson rotor-stator) applied as a final deaggregation step, leading to a slump height increase from 8 mm to 14 mm in the 24-hour static stability test per ASTM D4040. Manufacturing instructions therefore specify a jacketed vessel looped to a temperature control unit set at 22 ± 1°C. The finished paste, filled into 30 mL high-density polyethylene graduated applicators with Luer-lock tips and sealed with bromobutyl plunger stoppers, is subject to a 90-day shelf life at 30°C/65% RH stability protocol in which the assay by USP<425> liquid chromatography must remain between 90.0% and 110.0% of label claim and the sulfathiazole impurity must not exceed 2.0%. The primary market reference for the finished veterinary medicinal product is the Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6), and for exports to non-EU regions the specification is aligned with the oral paste general chapter of the Japanese Animal Drug Inspection Guidelines.
| Pharmaceutical form | Compendial standard reference | Typical active content (w/w or w/v) | Production process core parameter |
|---|---|---|---|
| Medicated feed premix | VICH GL48, national feed additive registries | 5–30% (masterbatch) | Stepwise dilution CV < 5% on 10 g sample |
| Film-coated tablet | USP Phthalylsulfathiazole Tablets, BP Veterinary | 70–88% of core weight | Granulation moisture window 1.5–2.2% |
| Oral suspension (aqueous) | USP Phthalylsulfathiazole Oral Suspension | 10–20% w/v | Viscosity at infinite shear 180–260 mPa·s |
| Oral paste | Ph. Eur. 0131 Semi-solid preparations, VICH GL9 | 25–35% w/w | Yield stress 230–270 Pa |
| Water-soluble powder (drinking water) | EU Directive 2002/32/EC, USP <621> | 1.5–3.0 g/L in final solution | Impurity ceiling 1.0% over 24 h |
| Oral bolus (ruminant) | BP Appendix XII B modified disintegration | 55–65% w/w | Crushing strength ≥12 kp |
Wet granulation endpoints and the risk of binder migration in phthalylsulphathiazole formulations
At production sites that routinely switch between sulfonamide-based and non-steroidal drug products in the same high-shear granulator train, cross-contamination risk and batch-to-batch variation in densification kinetics force an exceptionally narrow power-consumption endpoint definition. For a 600 L bottom-driven granulator processing a 160 kg batch using phthalylsulphathiazole, maize starch (Ph. Eur. grade), and microcrystalline cellulose (Avicel PH-101) at a ratio of 78:14:8, the impeller/chopper sequence at 145/1,500 rpm produces a characteristic torque curve that plateaus at 19–21 kW for a period of only 55–70 seconds before over-granulation leads to a sharp rise in agglomerate size distribution from a d50 of 180 µm to 320 µm. The operator must terminate binder addition (10% w/w pre-heated gelatin solution, 60°C) at a water activity trigger of 0.62 aw measured by an in-line near-infrared probe rather than by time or absolute liquid volume, because the hygroscopic variability of the starch—absorbing an additional 1.2% moisture at 50% RH storage—skews the granule porosity and subsequently the dissolution rate of the finished dosage below the Q=75% at 45 minutes threshold defined in USP <711>. Transfer to the fluid-bed dryer, accomplished within 3 minutes to avoid corona solidification in the bowl, demands an inlet temperature ramp from 45°C to a terminal plateau of 58°C at a product-bed depth not exceeding 18 cm. Exceeding 62°C for more than 15 minutes—a condition observed in the lobed zones of poorly baffled dryers—generates a phthalimido ring-opening degradation track visible as a shoulder on the principal HPLC peak at a relative retention time of 1.34, violating the monograph’s unspecified impurity limit of 0.5%. Finished granules are milled through a Conidur screen 1.25 mm and blended with the extragranular components: 2.0% crospovidone, 0.55% magnesium stearate, 0.15% colloidal silicon dioxide. The final tablet for the 1.0 g veterinary presentation, punched at 25 kN on a 51-station press, displays a hardness of 7–10 kp and a porosity of 8–12%, which has been correlated with a gastric fluid absorption lag time of 18–25 minutes in the fed-state calf stomach simulation (pH 3.5, 37°C). This manufacturing dataset is routinely benchmarked against the process analytical technology framework of ICH Q13 for continuous manufacturing readiness, although published data for phthalylsulphathiazole-specific continuous granulation is limited to feasibility studies using a twin-screw granulator with an L/D ratio of 25:1 and a screw configuration of 21 conveying elements, 6 kneading blocks at 60° pitch, and 4 discharge elements, operated at a screw speed of 250 rpm and a powder feed rate of 18 kg/h.
The production of an aqueous oral suspension for paediatric use—still registered in several WHO region 4 countries for the treatment of non-severe bacillary dysentery in children above 2 years—must overcome the inherent hydrophobic surface of the micronized active (d90 ≤50 µm) without resorting to surfactant levels that exceed the acceptable daily intake established in 21 CFR 172.840. A compounding protocol validated at a dedicated contract manufacturer in Jordan specifies the dispersion of 12.5 g phthalylsulphathiazole per 100 mL in a vehicle containing 0.15% w/v xanthan gum (USP/NF, viscosity 1200–1600 cP for a 1% solution), 0.02% w/v benzoic acid, and a sucrose-based density-adjusting syrup targeting a final specific gravity of 1.18–1.22 g/mL at 20°C. The colloid mill (rotor-stator clearance 0.15 mm, 3,200 rpm) recirculates the slurry until the mean particle size passes through a 150 µm wire cloth with less than 0.5% residue as per USP <429> laser diffraction verification, typically after 4 to 5 passes. A documented batch failure mode occurs when the hydration temperature of the xanthan gum phase falls below 55°C—the gel network does not fully develop, resulting in a viscosity of only 80 mPa·s at 20 rpm Brookfield spindle #3, which permits settling of the active to a sediment height ratio of 0.62 after 72 hours, failing the redispersibility clause of the BP Appendix XII A uniformity test for oral liquids. Conversely, viscosities above 350 mPa·s, encountered when the gum is heated beyond 80°C prior to mixing, impede the automated filling into 100 mL amber PET bottles at a line speed of 120 units per minute, causing a capping torque reject rate increase from a baseline of 0.2% to 3.1%. The terminal product, labelled with a 24-month shelf life at 25°C and a 15-day in-use period after first opening, must conform to the ICH Q1A(R2) intermediate stability condition of 30°C/65% RH and retain the preservative efficacy criterion B of Ph. Eur. 5.1.3.
